🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 Dr. John Cush #Strategy

🔴🔵 Red pill or blue pill?At the #GRAPPA2025 Adjacent-to-EULAR session, we stepped into the future of PsA: AI, immune phenotypes,D2T challenges, and innovative trial designs. Outstanding talks by Venerito,Zabotti, Kougkas,Van Mechelen,and the brilliant Fabian Proft. #EULAR2025

Clinical utility of large language models for osteoporosis referral triage: a pilot study Latika Olena Zimba Dana Doskaliuk Burhan Fatih Koçyiğit Vincenzo Venerito rmdopen.bmj.com/content/11/2/e…

It was a great congress and it was one of the most exciting part of the congress to meet in person with Prof Dimitrios P Bogdanos. He is such an amazing guide in my journey 🙏

🥳🥳🚀 What an exciting journey!! Full of excitement, collaboration and new ideas!! It was a great pleasure to be a part of EULAR family!! See you all in London next year!! Time to go back 🇹🇷 Vincenzo Venerito Kim Lauper ☮️🕊️ Chris Wincup Dr. John Cush EULAR Manouk de Hooge Ertugrul Cagri Bolek, MD MSc

✨ EULAR 2025 in beautiful Barcelona has come to an end — and what an unforgettable experience it was! 🇪🇸 I truly enjoyed the opportunity to network with inspiring colleagues, mentors, and friends. Here’s my quick Tops & Slops from this year’s congress: 🔝 TOP 1: The interest

🤖 Claude 3.5 Sonnet evaluated 50 osteoporosis cases against specialist doctors for risk assessment and treatment decisions 📊 90% accuracy in risk stratification, 90% agreement on referral decisions, completed assessments in 3 minutes vs 10-12 minutes for specialists ⚖️ While

💊 NORD-STAR trial studied 296 early rheumatoid arthritis patients comparing glucocorticoids vs biologics on PCSK9 levels over 24 weeks 📈 Glucocorticoids increased PCSK9 levels significantly more than biologics (276 pg/mL difference), with strongest effects in patients with RF,

🩺 Pilot study tested personalized rituximab spacing in 19 ANCA vasculitis patients based on individual relapse risk after standard 18-month treatment 📅 High-risk patients continued 6-monthly infusions, intermediate-risk received 12-monthly spacing, and low-risk switched to

💡 Danish study emulated randomized trial using registry data from 450 fibromyalgia patients with high pain education needs who completed 2-day therapeutic education program 📊 At 9-month follow-up: patients achieving good educational outcomes (reduced learning needs <5/10)

🔬 Dutch-Swedish study analyzed autoantibody patterns in 333 RA patients and 68 pre-symptomatic individuals who later developed RA, investigating co-occurrence of different antibody types and isotypes 📊 No specific patterns emerged based on antigen specificity or antibody

📈 Italian study analyzed 16,254 autoimmune rheumatic disease diagnoses from 2017-2023 in 6.5 million inhabitants during COVID-19 pandemic using administrative health data 📊 After initial decline in 2020 (32% drop), significant increases emerged 2021-2023: overall 22% rise by

🔬 Age at diagnosis shows opposite effects in different JIA categories - younger diagnosis predicts better remission in oligoarthritis but worse outcomes in seronegative polyarthritis, particularly affecting females differently than males. 📊 Nordic cohort study reveals striking

💊 Rituximab-mycophenolate combination dramatically improved cardiac outcomes in 10 systemic sclerosis patients refractory to cyclophosphamide - all patients showed reduced troponin T levels, decreased ventricular arrhythmias, and improved left ventricular function. 🔬 Despite

🚀🚀 Are you interested in AI in the field of rheumatology? My recent review on AI applications and challenges in RA, axSpA and PsA is now online 😎😎 Vincenzo Venerito Diego Benavent Prof Dimitrios P Bogdanos Ertugrul Cagri Bolek, MD MSc Sakarya Üniversitesi journals.sagepub.com/doi/10.1177/17…

💬 The real strength of a doctor is their colleagues. The real secret of a researcher’s success? Their network. But there are very few networks like Digital Rheumatology Network! I still vividly remember my first Digital Rheumatology Day in 2022: I was there, honored to receive

👁️🦷 High-frequency lacrimal-gland ultrasound sharpens #Sjögren diagnostics. 📝 OMERACT grade ≥2 on 6–24 MHz lacrimal gland ultrasound ✅ Specificity 87.5%, PPV 80%—better than salivary-gland US in this cohort ✅ Sensitivity 61.5%, NPV 73.3% 🔗 Strong association with

🌊 On Autoimmunity Reviews a true pan-Mediterranean effort with my dear friends Prof. Emre Bilgin and Prof. Demetrios Bogdanos! We are exploring the emerging role of GLP-1 receptor agonists beyond diabetes and obesity — and their highly promising potential in rheumatic and